A Study to Evaluate the Safety, Tolerability, and Exploratory Efficacy of IMS001 in Subjects With Multiple Sclerosis

Inclusion Criteria:

• Provides signed and dated informed consent in accordance with local regulations.
• 18 to 65 years of age.
• Diagnosis of MS.
• Has had an inadequate response DMTs.
• EDSS within protocol parameters.
• Able and willing to undergo MRIs.
• Must be clinically stable for 1 month prior to Day 1.

Exclusion Criteria:

• Has a known or suspected hypersensitivity to human serum albumin, diphenhydramine,acetaminophen, methylprednisolone, or any of the components of IMS001.
• Has history of excluded medications, per protocol, prior to Day 1.
• Has a history of neoplastic disease except for basal cell carcinoma, non-metastaticsquamous cell carcinoma of the skin that has been excised with clean margins, oradequately treated in-situ carcinoma of the cervix.
• Prior history of any other autoimmune disease, myelodysplasia, or hematologic disease.
• Prior treatment with any allogeneic cell therapy or tissue transplant.
• Prior history of smoking equivalent to ˃20 cumulative pack years of cigarettes.
• Recent clinically significant infection during the Screening Phase.
• Has any medical or psychiatric condition that would impact outcome or participation inthe study.
• Has clinically significant abnormal findings on the electrocardiogram (ECG) during theScreening Phase.
• Has known or documented human immunodeficiency virus (HIV) infection or activeHepatitis B, or C.
• Has an elevated liver function test abnormality during the Screening Phase.
• Has abnormalities of blood count during the Screening Phase.
• Has laboratory abnormalities of renal function during the Screening Phase.
• Has other clinically significant laboratory abnormalities during Screening Phase.
• Body weight ≥120 kg.
• Women pregnant, breast feeding, or planning to become pregnant during the study.
• Is unavailable for the duration of the trial, is likely to be noncompliant with theprotocol, or is generally felt to be unsuitable by the principal investigator.
• Current or recent participation in any other clinical or device trials within 3 monthsprior to Day 1.